Thermo Fisher Scientific Inc. (NYSE: TMO) Stock Competitors & Peer Comparison
See TMO's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for TMO and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| TMO | $574.30 | -0.43% | 213.4B | 24.79 | $23.16 | +0.31% |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.73% |
| DHR | $194.98 | -0.61% | 137.1B | 24.45 | $7.98 | +0.73% |
| IDXX | $559.07 | +0.05% | 44.1B | 41.17 | $13.58 | N/A |
| A | $138.37 | -0.25% | 39.1B | 23.82 | $5.81 | +0.73% |
| IQV | $235.02 | -1.16% | 38.7B | 19.38 | $12.13 | N/A |
| NTRA | $267.76 | -0.70% | 38.3B | -168.40 | -$1.59 | N/A |
| ILMN | $205.10 | +0.00% | 31B | 40.78 | $5.03 | N/A |
| MTD | $1,416.30 | +2.59% | 28.6B | 32.58 | $43.51 | N/A |
| DGX | $233.01 | -0.55% | 25.7B | 22.98 | $10.14 | +1.41% |
Stock Comparison
Danaher Corporation (NYSE: DHR-PB)
TMO vs DHR-PB Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, TMO's ROE is +0.13%, compared to DHR-PB's ROE of +0.08%. Regarding short-term risk, TMO is more volatile compared to DHR-PB. This indicates higher risk in terms of short-term price fluctuations for TMO.Check DHR-PB's competition here
Danaher Corporation (NYSE: DHR)
TMO vs DHR Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, DHR has a market cap of 137.1B. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while DHR trades at $194.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas DHR's P/E ratio is 24.45. In terms of profitability, TMO's ROE is +0.13%, compared to DHR's ROE of +0.08%. Regarding short-term risk, TMO is less volatile compared to DHR. This indicates lower risk in terms of short-term price fluctuations for TMO.Check DHR's competition here
IDEXX Laboratories, Inc. (NASDAQ: IDXX)
TMO vs IDXX Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, IDXX has a market cap of 44.1B. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while IDXX trades at $559.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas IDXX's P/E ratio is 41.17. In terms of profitability, TMO's ROE is +0.13%, compared to IDXX's ROE of +0.71%. Regarding short-term risk, TMO is more volatile compared to IDXX. This indicates higher risk in terms of short-term price fluctuations for TMO.Check IDXX's competition here
Agilent Technologies, Inc. (NYSE: A)
TMO vs A Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, A has a market cap of 39.1B. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while A trades at $138.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas A's P/E ratio is 23.82. In terms of profitability, TMO's ROE is +0.13%, compared to A's ROE of +0.21%. Regarding short-term risk, TMO is less volatile compared to A. This indicates lower risk in terms of short-term price fluctuations for TMO.Check A's competition here
IQVIA Holdings Inc. (NYSE: IQV)
TMO vs IQV Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, IQV has a market cap of 38.7B. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while IQV trades at $235.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas IQV's P/E ratio is 19.38. In terms of profitability, TMO's ROE is +0.13%, compared to IQV's ROE of +0.22%. Regarding short-term risk, TMO is less volatile compared to IQV. This indicates lower risk in terms of short-term price fluctuations for TMO.Check IQV's competition here
Natera, Inc. (NASDAQ: NTRA)
TMO vs NTRA Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, NTRA has a market cap of 38.3B. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while NTRA trades at $267.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas NTRA's P/E ratio is -168.40. In terms of profitability, TMO's ROE is +0.13%, compared to NTRA's ROE of -0.15%. Regarding short-term risk, TMO is less volatile compared to NTRA. This indicates lower risk in terms of short-term price fluctuations for TMO.Check NTRA's competition here
Illumina, Inc. (NASDAQ: ILMN)
TMO vs ILMN Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, ILMN has a market cap of 31B. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while ILMN trades at $205.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas ILMN's P/E ratio is 40.78. In terms of profitability, TMO's ROE is +0.13%, compared to ILMN's ROE of +0.31%. Regarding short-term risk, TMO is less volatile compared to ILMN. This indicates lower risk in terms of short-term price fluctuations for TMO.Check ILMN's competition here
Mettler-Toledo International Inc. (NYSE: MTD)
TMO vs MTD Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, MTD has a market cap of 28.6B. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while MTD trades at $1,416.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas MTD's P/E ratio is 32.58. In terms of profitability, TMO's ROE is +0.13%, compared to MTD's ROE of -12.00%. Regarding short-term risk, TMO is less volatile compared to MTD. This indicates lower risk in terms of short-term price fluctuations for TMO.Check MTD's competition here
Quest Diagnostics Incorporated (NYSE: DGX)
TMO vs DGX Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, DGX has a market cap of 25.7B. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while DGX trades at $233.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas DGX's P/E ratio is 22.98. In terms of profitability, TMO's ROE is +0.13%, compared to DGX's ROE of +0.14%. Regarding short-term risk, TMO is more volatile compared to DGX. This indicates higher risk in terms of short-term price fluctuations for TMO.Check DGX's competition here
Labcorp Holdings Inc. (NYSE: LH)
TMO vs LH Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, LH has a market cap of 25.4B. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while LH trades at $309.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas LH's P/E ratio is 18.36. In terms of profitability, TMO's ROE is +0.13%, compared to LH's ROE of +0.12%. Regarding short-term risk, TMO is less volatile compared to LH. This indicates lower risk in terms of short-term price fluctuations for TMO.Check LH's competition here
Waters Corporation (NYSE: WAT)
TMO vs WAT Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, WAT has a market cap of 24.6B. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while WAT trades at $377.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas WAT's P/E ratio is 27.78. In terms of profitability, TMO's ROE is +0.13%, compared to WAT's ROE of +0.08%. Regarding short-term risk, TMO is less volatile compared to WAT. This indicates lower risk in terms of short-term price fluctuations for TMO.Check WAT's competition here
Guardant Health, Inc. (NASDAQ: GH)
TMO vs GH Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, GH has a market cap of 21.5B. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while GH trades at $161.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas GH's P/E ratio is -62.79. In terms of profitability, TMO's ROE is +0.13%, compared to GH's ROE of +2.11%. Regarding short-term risk, TMO is less volatile compared to GH. This indicates lower risk in terms of short-term price fluctuations for TMO.Check GH's competition here
Exact Sciences Corporation (NASDAQ: EXAS)
TMO vs EXAS Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas EXAS's P/E ratio is -95.37. In terms of profitability, TMO's ROE is +0.13%, compared to EXAS's ROE of -0.09%. Regarding short-term risk, TMO is more volatile compared to EXAS. This indicates higher risk in terms of short-term price fluctuations for TMO.Check EXAS's competition here
Illumina, Inc. Common Stock Ex-distribution When-Issued (NASDAQ: ILMNV)
TMO vs ILMNV Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas ILMNV's P/E ratio is N/A. In terms of profitability, TMO's ROE is +0.13%, compared to ILMNV's ROE of N/A. Regarding short-term risk, TMO is more volatile compared to ILMNV. This indicates higher risk in terms of short-term price fluctuations for TMO.Check ILMNV's competition here
Medpace Holdings, Inc. (NASDAQ: MEDP)
TMO vs MEDP Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, MEDP has a market cap of 16.1B. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while MEDP trades at $577.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas MEDP's P/E ratio is 36.27. In terms of profitability, TMO's ROE is +0.13%, compared to MEDP's ROE of +1.10%. Regarding short-term risk, TMO is more volatile compared to MEDP. This indicates higher risk in terms of short-term price fluctuations for TMO.Check MEDP's competition here
PerkinElmer, Inc. (NYSE: PKI)
TMO vs PKI Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas PKI's P/E ratio is 41.45. In terms of profitability, TMO's ROE is +0.13%, compared to PKI's ROE of +0.03%. Regarding short-term risk, TMO is more volatile compared to PKI. This indicates higher risk in terms of short-term price fluctuations for TMO.Check PKI's competition here
Revvity, Inc. (NYSE: RVTY)
TMO vs RVTY Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, RVTY has a market cap of 12.6B. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while RVTY trades at $112.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas RVTY's P/E ratio is 21.98. In terms of profitability, TMO's ROE is +0.13%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, TMO is less volatile compared to RVTY. This indicates lower risk in terms of short-term price fluctuations for TMO.Check RVTY's competition here
ICON Public Limited Company (NASDAQ: ICLR)
TMO vs ICLR Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, ICLR has a market cap of 12.5B. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while ICLR trades at $163.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas ICLR's P/E ratio is 13.34. In terms of profitability, TMO's ROE is +0.13%, compared to ICLR's ROE of +0.04%. Regarding short-term risk, TMO is less volatile compared to ICLR. This indicates lower risk in terms of short-term price fluctuations for TMO.Check ICLR's competition here
Charles River Laboratories International, Inc. (NYSE: CRL)
TMO vs CRL Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, CRL has a market cap of 11.2B. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while CRL trades at $232.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas CRL's P/E ratio is 23.25. In terms of profitability, TMO's ROE is +0.13%, compared to CRL's ROE of -0.06%. Regarding short-term risk, TMO is less volatile compared to CRL. This indicates lower risk in terms of short-term price fluctuations for TMO.Check CRL's competition here
Qiagen N.V. (NYSE: QGEN)
TMO vs QGEN Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, QGEN has a market cap of 8.5B. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while QGEN trades at $41.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas QGEN's P/E ratio is 17.25. In terms of profitability, TMO's ROE is +0.13%, compared to QGEN's ROE of +0.11%. Regarding short-term risk, TMO is more volatile compared to QGEN. This indicates higher risk in terms of short-term price fluctuations for TMO.Check QGEN's competition here
BillionToOne, Inc. (NASDAQ: BLLN)
TMO vs BLLN Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, BLLN has a market cap of 6.4B. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while BLLN trades at $138.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas BLLN's P/E ratio is 252.00. In terms of profitability, TMO's ROE is +0.13%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, TMO is less volatile compared to BLLN. This indicates lower risk in terms of short-term price fluctuations for TMO.Check BLLN's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
TMO vs TWST Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, TWST has a market cap of 5.7B. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while TWST trades at $91.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas TWST's P/E ratio is -42.98. In terms of profitability, TMO's ROE is +0.13%, compared to TWST's ROE of -0.17%. Regarding short-term risk, TMO is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for TMO.Check TWST's competition here
Sotera Health Company (NASDAQ: SHC)
TMO vs SHC Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, SHC has a market cap of 5.1B. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while SHC trades at $17.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas SHC's P/E ratio is 19.84. In terms of profitability, TMO's ROE is +0.13%, compared to SHC's ROE of +0.21%. Regarding short-term risk, TMO is more volatile compared to SHC. This indicates higher risk in terms of short-term price fluctuations for TMO.Check SHC's competition here
RadNet, Inc. (NASDAQ: RDNT)
TMO vs RDNT Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, RDNT has a market cap of 5B. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while RDNT trades at $63.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas RDNT's P/E ratio is 138.65. In terms of profitability, TMO's ROE is +0.13%, compared to RDNT's ROE of -0.01%. Regarding short-term risk, TMO is less volatile compared to RDNT. This indicates lower risk in terms of short-term price fluctuations for TMO.Check RDNT's competition here
Syneos Health, Inc. (NASDAQ: SYNH)
TMO vs SYNH Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas SYNH's P/E ratio is 61.40. In terms of profitability, TMO's ROE is +0.13%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, TMO is more volatile compared to SYNH. This indicates higher risk in terms of short-term price fluctuations for TMO.Check SYNH's competition here
Veracyte, Inc. (NASDAQ: VCYT)
TMO vs VCYT Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, VCYT has a market cap of 3.7B. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while VCYT trades at $46.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas VCYT's P/E ratio is 23.16. In terms of profitability, TMO's ROE is +0.13%, compared to VCYT's ROE of +0.09%. Regarding short-term risk, TMO is less volatile compared to VCYT. This indicates lower risk in terms of short-term price fluctuations for TMO.Check VCYT's competition here
Olink Holding AB (publ) (NASDAQ: OLK)
TMO vs OLK Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas OLK's P/E ratio is -96.59. In terms of profitability, TMO's ROE is +0.13%, compared to OLK's ROE of -0.07%. Regarding short-term risk, TMO is more volatile compared to OLK. This indicates higher risk in terms of short-term price fluctuations for TMO.Check OLK's competition here
Neogen Corporation (NASDAQ: NEOG)
TMO vs NEOG Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, NEOG has a market cap of 2.6B. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while NEOG trades at $12.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas NEOG's P/E ratio is 43.00. In terms of profitability, TMO's ROE is +0.13%, compared to NEOG's ROE of -0.00%. Regarding short-term risk, TMO is less volatile compared to NEOG. This indicates lower risk in terms of short-term price fluctuations for TMO.Check NEOG's competition here
CareDx, Inc (NASDAQ: CDNA)
TMO vs CDNA Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, CDNA has a market cap of 2.3B. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while CDNA trades at $43.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas CDNA's P/E ratio is 52.04. In terms of profitability, TMO's ROE is +0.13%, compared to CDNA's ROE of +0.33%. Regarding short-term risk, TMO is less volatile compared to CDNA. This indicates lower risk in terms of short-term price fluctuations for TMO.Check CDNA's competition here
Personalis, Inc. (NASDAQ: PSNL)
TMO vs PSNL Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, PSNL has a market cap of 1.4B. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while PSNL trades at $12.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas PSNL's P/E ratio is -12.41. In terms of profitability, TMO's ROE is +0.13%, compared to PSNL's ROE of -0.44%. Regarding short-term risk, TMO is less volatile compared to PSNL. This indicates lower risk in terms of short-term price fluctuations for TMO.Check PSNL's competition here
Castle Biosciences, Inc. (NASDAQ: CSTL)
TMO vs CSTL Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, CSTL has a market cap of 849.2M. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while CSTL trades at $28.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas CSTL's P/E ratio is -63.64. In terms of profitability, TMO's ROE is +0.13%, compared to CSTL's ROE of -0.04%. Regarding short-term risk, TMO is less volatile compared to CSTL. This indicates lower risk in terms of short-term price fluctuations for TMO.Check CSTL's competition here
GRAIL, Inc. Common Stock (NASDAQ: GRALV)
TMO vs GRALV Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas GRALV's P/E ratio is N/A. In terms of profitability, TMO's ROE is +0.13%, compared to GRALV's ROE of N/A. Regarding short-term risk, TMO is less volatile compared to GRALV. This indicates lower risk in terms of short-term price fluctuations for TMO.Check GRALV's competition here
Fulgent Genetics, Inc. (NASDAQ: FLGT)
TMO vs FLGT Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, FLGT has a market cap of 470M. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while FLGT trades at $16.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas FLGT's P/E ratio is 1655.00. In terms of profitability, TMO's ROE is +0.13%, compared to FLGT's ROE of -0.08%. Regarding short-term risk, TMO is less volatile compared to FLGT. This indicates lower risk in terms of short-term price fluctuations for TMO.Check FLGT's competition here
Global Cord Blood Corporation (NYSE: CO)
TMO vs CO Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas CO's P/E ratio is 5.06. In terms of profitability, TMO's ROE is +0.13%, compared to CO's ROE of +0.11%. Regarding short-term risk, TMO is less volatile compared to CO. This indicates lower risk in terms of short-term price fluctuations for TMO.Check CO's competition here
NeoGenomics, Inc. (NASDAQ: NEO)
TMO vs NEO Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, NEO has a market cap of 392.9M. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while NEO trades at $15.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas NEO's P/E ratio is 117.62. In terms of profitability, TMO's ROE is +0.13%, compared to NEO's ROE of -0.06%. Regarding short-term risk, TMO is less volatile compared to NEO. This indicates lower risk in terms of short-term price fluctuations for TMO.Check NEO's competition here
Prenetics Global Limited (NASDAQ: PRENW)
TMO vs PRENW Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, PRENW has a market cap of 360.8M. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while PRENW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas PRENW's P/E ratio is N/A. In terms of profitability, TMO's ROE is +0.13%, compared to PRENW's ROE of -0.47%. Regarding short-term risk, TMO is more volatile compared to PRENW. This indicates higher risk in terms of short-term price fluctuations for TMO.Check PRENW's competition here
Prenetics Global Limited (NASDAQ: PRE)
TMO vs PRE Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, PRE has a market cap of 316.9M. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while PRE trades at $18.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas PRE's P/E ratio is -9.05. In terms of profitability, TMO's ROE is +0.13%, compared to PRE's ROE of -0.47%. Regarding short-term risk, TMO is less volatile compared to PRE. This indicates lower risk in terms of short-term price fluctuations for TMO.Check PRE's competition here
Standard BioTools Inc. (NASDAQ: FLDM)
TMO vs FLDM Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas FLDM's P/E ratio is -4.74. In terms of profitability, TMO's ROE is +0.13%, compared to FLDM's ROE of +0.17%. Regarding short-term risk, TMO is less volatile compared to FLDM. This indicates lower risk in terms of short-term price fluctuations for TMO.Check FLDM's competition here
Myriad Genetics, Inc. (NASDAQ: MYGN)
TMO vs MYGN Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, MYGN has a market cap of 270.1M. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while MYGN trades at $2.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas MYGN's P/E ratio is -22.00. In terms of profitability, TMO's ROE is +0.13%, compared to MYGN's ROE of -0.33%. Regarding short-term risk, TMO is less volatile compared to MYGN. This indicates lower risk in terms of short-term price fluctuations for TMO.Check MYGN's competition here
Trinity Biotech plc (NASDAQ: TRIB)
TMO vs TRIB Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, TRIB has a market cap of 234.9M. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while TRIB trades at $11.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas TRIB's P/E ratio is -3.01. In terms of profitability, TMO's ROE is +0.13%, compared to TRIB's ROE of +0.68%. Regarding short-term risk, TMO is less volatile compared to TRIB. This indicates lower risk in terms of short-term price fluctuations for TMO.Check TRIB's competition here
Biodesix, Inc. (NASDAQ: BDSX)
TMO vs BDSX Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, BDSX has a market cap of 172.6M. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while BDSX trades at $21.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas BDSX's P/E ratio is -5.22. In terms of profitability, TMO's ROE is +0.13%, compared to BDSX's ROE of -21.01%. Regarding short-term risk, TMO is less volatile compared to BDSX. This indicates lower risk in terms of short-term price fluctuations for TMO.Check BDSX's competition here
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)
TMO vs IMDX Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, IMDX has a market cap of 150.1M. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while IMDX trades at $4.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas IMDX's P/E ratio is -3.91. In terms of profitability, TMO's ROE is +0.13%, compared to IMDX's ROE of +3.81%. Regarding short-term risk, TMO is less volatile compared to IMDX. This indicates lower risk in terms of short-term price fluctuations for TMO.Check IMDX's competition here
Genetron Holdings Limited (NASDAQ: GTH)
TMO vs GTH Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas GTH's P/E ratio is -1.11. In terms of profitability, TMO's ROE is +0.13%, compared to GTH's ROE of -1.01%. Regarding short-term risk, TMO is more volatile compared to GTH. This indicates higher risk in terms of short-term price fluctuations for TMO.Check GTH's competition here
Genetic Technologies Limited (NASDAQ: GENE)
TMO vs GENE Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas GENE's P/E ratio is -38.25. In terms of profitability, TMO's ROE is +0.13%, compared to GENE's ROE of -1.85%. Regarding short-term risk, TMO is more volatile compared to GENE. This indicates higher risk in terms of short-term price fluctuations for TMO.Check GENE's competition here
Exagen Inc. (NASDAQ: XGN)
TMO vs XGN Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, XGN has a market cap of 109.4M. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while XGN trades at $4.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas XGN's P/E ratio is -6.12. In terms of profitability, TMO's ROE is +0.13%, compared to XGN's ROE of -1.14%. Regarding short-term risk, TMO is less volatile compared to XGN. This indicates lower risk in terms of short-term price fluctuations for TMO.Check XGN's competition here
Sera Prognostics, Inc. (NASDAQ: SERA)
TMO vs SERA Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, SERA has a market cap of 79.8M. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while SERA trades at $2.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas SERA's P/E ratio is -3.22. In terms of profitability, TMO's ROE is +0.13%, compared to SERA's ROE of -0.41%. Regarding short-term risk, TMO is less volatile compared to SERA. This indicates lower risk in terms of short-term price fluctuations for TMO.Check SERA's competition here
Atlantic International Corp. (NASDAQ: ATLN)
TMO vs ATLN Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, ATLN has a market cap of 73.2M. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while ATLN trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas ATLN's P/E ratio is -0.68. In terms of profitability, TMO's ROE is +0.13%, compared to ATLN's ROE of +14.94%. Regarding short-term risk, TMO is less volatile compared to ATLN. This indicates lower risk in terms of short-term price fluctuations for TMO.Check ATLN's competition here
DarioHealth Corp. (NASDAQ: DRIO)
TMO vs DRIO Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, DRIO has a market cap of 53.2M. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while DRIO trades at $7.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas DRIO's P/E ratio is -1.24. In terms of profitability, TMO's ROE is +0.13%, compared to DRIO's ROE of +0.93%. Regarding short-term risk, TMO is less volatile compared to DRIO. This indicates lower risk in terms of short-term price fluctuations for TMO.Check DRIO's competition here
Precipio, Inc. (NASDAQ: PRPO)
TMO vs PRPO Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, PRPO has a market cap of 38.7M. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while PRPO trades at $21.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas PRPO's P/E ratio is -83.27. In terms of profitability, TMO's ROE is +0.13%, compared to PRPO's ROE of -0.07%. Regarding short-term risk, TMO is less volatile compared to PRPO. This indicates lower risk in terms of short-term price fluctuations for TMO.Check PRPO's competition here
Akumin Inc. (NASDAQ: AKU)
TMO vs AKU Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas AKU's P/E ratio is -0.13. In terms of profitability, TMO's ROE is +0.13%, compared to AKU's ROE of -5.32%. Regarding short-term risk, TMO is less volatile compared to AKU. This indicates lower risk in terms of short-term price fluctuations for TMO.Check AKU's competition here
MDxHealth S.A. (NASDAQ: MDXH)
TMO vs MDXH Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, MDXH has a market cap of 21.5M. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while MDXH trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas MDXH's P/E ratio is -1.10. In terms of profitability, TMO's ROE is +0.13%, compared to MDXH's ROE of +4.03%. Regarding short-term risk, TMO is less volatile compared to MDXH. This indicates lower risk in terms of short-term price fluctuations for TMO.Check MDXH's competition here
Chembio Diagnostics, Inc. (NASDAQ: CEMI)
TMO vs CEMI Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas CEMI's P/E ratio is -0.63. In terms of profitability, TMO's ROE is +0.13%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, TMO is more volatile compared to CEMI. This indicates higher risk in terms of short-term price fluctuations for TMO.Check CEMI's competition here
Enzo Biochem, Inc. (NYSE: ENZ)
TMO vs ENZ Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas ENZ's P/E ratio is -2.24. In terms of profitability, TMO's ROE is +0.13%, compared to ENZ's ROE of -0.10%. Regarding short-term risk, TMO is less volatile compared to ENZ. This indicates lower risk in terms of short-term price fluctuations for TMO.Check ENZ's competition here
Psychemedics Corporation (NASDAQ: PMD)
TMO vs PMD Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas PMD's P/E ratio is -5.24. In terms of profitability, TMO's ROE is +0.13%, compared to PMD's ROE of -0.32%. Regarding short-term risk, TMO is more volatile compared to PMD. This indicates higher risk in terms of short-term price fluctuations for TMO.Check PMD's competition here
23andMe Holding Co. (NASDAQ: ME)
TMO vs ME Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas ME's P/E ratio is -0.03. In terms of profitability, TMO's ROE is +0.13%, compared to ME's ROE of -42.03%. Regarding short-term risk, TMO is more volatile compared to ME. This indicates higher risk in terms of short-term price fluctuations for TMO.Check ME's competition here
Mainz Biomed B.V. (NASDAQ: MYNZ)
TMO vs MYNZ Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas MYNZ's P/E ratio is -0.68. In terms of profitability, TMO's ROE is +0.13%, compared to MYNZ's ROE of -10.25%. Regarding short-term risk, TMO is less volatile compared to MYNZ. This indicates lower risk in terms of short-term price fluctuations for TMO.Check MYNZ's competition here
Quantum Cyber N.V. (NASDAQ: QUCY)
TMO vs QUCY Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, QUCY has a market cap of 14.3M. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while QUCY trades at $1.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas QUCY's P/E ratio is -0.05. In terms of profitability, TMO's ROE is +0.13%, compared to QUCY's ROE of -3.26%. Regarding short-term risk, TMO is less volatile compared to QUCY. This indicates lower risk in terms of short-term price fluctuations for TMO.Check QUCY's competition here
Bionano Genomics, Inc. (NASDAQ: BNGO)
TMO vs BNGO Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, BNGO has a market cap of 12.3M. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while BNGO trades at $1.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas BNGO's P/E ratio is -0.24. In terms of profitability, TMO's ROE is +0.13%, compared to BNGO's ROE of -0.71%. Regarding short-term risk, TMO is less volatile compared to BNGO. This indicates lower risk in terms of short-term price fluctuations for TMO.Check BNGO's competition here
Check-Cap Ltd. (NASDAQ: CHEK)
TMO vs CHEK Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas CHEK's P/E ratio is -0.43. In terms of profitability, TMO's ROE is +0.13%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, TMO is less volatile compared to CHEK. This indicates lower risk in terms of short-term price fluctuations for TMO.Check CHEK's competition here
Centogene N.V. (NASDAQ: CNTG)
TMO vs CNTG Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas CNTG's P/E ratio is -0.23. In terms of profitability, TMO's ROE is +0.13%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, TMO is more volatile compared to CNTG. This indicates higher risk in terms of short-term price fluctuations for TMO.Check CNTG's competition here
Burning Rock Biotech Limited (NASDAQ: BNR)
TMO vs BNR Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, BNR has a market cap of 9.3M. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while BNR trades at $8.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas BNR's P/E ratio is -10.73. In terms of profitability, TMO's ROE is +0.13%, compared to BNR's ROE of -0.11%. Regarding short-term risk, TMO is more volatile compared to BNR. This indicates higher risk in terms of short-term price fluctuations for TMO.Check BNR's competition here
Advanced Biomed Inc. Common Stock (NASDAQ: ADVB)
TMO vs ADVB Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, ADVB has a market cap of 8.7M. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while ADVB trades at $8.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas ADVB's P/E ratio is -72.73. In terms of profitability, TMO's ROE is +0.13%, compared to ADVB's ROE of -0.21%. Regarding short-term risk, TMO is less volatile compared to ADVB. This indicates lower risk in terms of short-term price fluctuations for TMO.Check ADVB's competition here
Check-Cap Ltd. Ordinary Share (NASDAQ: MBAI)
TMO vs MBAI Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, MBAI has a market cap of 7.4M. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while MBAI trades at $1.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas MBAI's P/E ratio is 1.58. In terms of profitability, TMO's ROE is +0.13%, compared to MBAI's ROE of +4.17%. Regarding short-term risk, TMO is less volatile compared to MBAI. This indicates lower risk in terms of short-term price fluctuations for TMO.Check MBAI's competition here
Applied DNA Sciences, Inc. (NASDAQ: APDN)
TMO vs APDN Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas APDN's P/E ratio is -0.10. In terms of profitability, TMO's ROE is +0.13%, compared to APDN's ROE of -6.53%. Regarding short-term risk, TMO is less volatile compared to APDN. This indicates lower risk in terms of short-term price fluctuations for TMO.Check APDN's competition here
Invitae Corporation (NYSE: NVTA)
TMO vs NVTA Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas NVTA's P/E ratio is -0.00. In terms of profitability, TMO's ROE is +0.13%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, TMO is less volatile compared to NVTA. This indicates lower risk in terms of short-term price fluctuations for TMO.Check NVTA's competition here
LumiraDx Limited (NASDAQ: LMDX)
TMO vs LMDX Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas LMDX's P/E ratio is -0.01. In terms of profitability, TMO's ROE is +0.13%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, TMO is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for TMO.Check LMDX's competition here
LumiraDx Limited (NASDAQ: LMDXW)
TMO vs LMDXW Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, TMO's ROE is +0.13%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, TMO is less volatile compared to LMDXW. This indicates lower risk in terms of short-term price fluctuations for TMO.Check LMDXW's competition here
ENDRA Life Sciences Inc. (NASDAQ: NDRA)
TMO vs NDRA Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, NDRA has a market cap of 3.6M. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while NDRA trades at $4.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas NDRA's P/E ratio is -0.61. In terms of profitability, TMO's ROE is +0.13%, compared to NDRA's ROE of -5.13%. Regarding short-term risk, TMO is less volatile compared to NDRA. This indicates lower risk in terms of short-term price fluctuations for TMO.Check NDRA's competition here
DermTech, Inc. (NASDAQ: DMTK)
TMO vs DMTK Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas DMTK's P/E ratio is -0.04. In terms of profitability, TMO's ROE is +0.13%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, TMO is less volatile compared to DMTK. This indicates lower risk in terms of short-term price fluctuations for TMO.Check DMTK's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAF)
TMO vs BIAF Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, BIAF has a market cap of 2.8M. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while BIAF trades at $0.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas BIAF's P/E ratio is -0.07. In terms of profitability, TMO's ROE is +0.13%, compared to BIAF's ROE of -3.59%. Regarding short-term risk, TMO is less volatile compared to BIAF. This indicates lower risk in terms of short-term price fluctuations for TMO.Check BIAF's competition here
Inotiv, Inc. (NASDAQ: NOTV)
TMO vs NOTV Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas NOTV's P/E ratio is -0.03. In terms of profitability, TMO's ROE is +0.13%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, TMO is less volatile compared to NOTV. This indicates lower risk in terms of short-term price fluctuations for TMO.Check NOTV's competition here
SeqLL Inc. (NASDAQ: SQL)
TMO vs SQL Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas SQL's P/E ratio is -0.40. In terms of profitability, TMO's ROE is +0.13%, compared to SQL's ROE of +38.02%. Regarding short-term risk, TMO is less volatile compared to SQL. This indicates lower risk in terms of short-term price fluctuations for TMO.Check SQL's competition here
Aspira Women's Health Inc. (NASDAQ: AWH)
TMO vs AWH Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas AWH's P/E ratio is -0.09. In terms of profitability, TMO's ROE is +0.13%, compared to AWH's ROE of +2.03%. Regarding short-term risk, TMO is more volatile compared to AWH. This indicates higher risk in terms of short-term price fluctuations for TMO.Check AWH's competition here
Intelligent Bio Solutions Inc. (NASDAQ: INBS)
TMO vs INBS Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, INBS has a market cap of 1.2M. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while INBS trades at $1.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas INBS's P/E ratio is -0.21. In terms of profitability, TMO's ROE is +0.13%, compared to INBS's ROE of -1.74%. Regarding short-term risk, TMO is less volatile compared to INBS. This indicates lower risk in terms of short-term price fluctuations for TMO.Check INBS's competition here
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM)
TMO vs HTGM Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas HTGM's P/E ratio is -0.03. In terms of profitability, TMO's ROE is +0.13%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, TMO is more volatile compared to HTGM. This indicates higher risk in terms of short-term price fluctuations for TMO.Check HTGM's competition here
Biocept, Inc. (NASDAQ: BIOC)
TMO vs BIOC Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas BIOC's P/E ratio is -0.01. In terms of profitability, TMO's ROE is +0.13%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, TMO is less volatile compared to BIOC. This indicates lower risk in terms of short-term price fluctuations for TMO.Check BIOC's competition here
iSpecimen Inc. (NASDAQ: ISPC)
TMO vs ISPC Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, ISPC has a market cap of 262.4K. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while ISPC trades at $1.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas ISPC's P/E ratio is -0.06. In terms of profitability, TMO's ROE is +0.13%, compared to ISPC's ROE of -5.85%. Regarding short-term risk, TMO is less volatile compared to ISPC. This indicates lower risk in terms of short-term price fluctuations for TMO.Check ISPC's competition here
SeqLL Inc. (NASDAQ: SQLLW)
TMO vs SQLLW Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, TMO's ROE is +0.13%, compared to SQLLW's ROE of +38.02%. Regarding short-term risk, TMO is less volatile compared to SQLLW. This indicates lower risk in terms of short-term price fluctuations for TMO.Check SQLLW's competition here
Check-Cap Ltd (NASDAQ: CHEKZ)
TMO vs CHEKZ Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, TMO's ROE is +0.13%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, TMO is less volatile compared to CHEKZ. This indicates lower risk in terms of short-term price fluctuations for TMO.Check CHEKZ's competition here
23andMe Holding Co. (NASDAQ: MEUSW)
TMO vs MEUSW Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas MEUSW's P/E ratio is N/A. In terms of profitability, TMO's ROE is +0.13%, compared to MEUSW's ROE of -42.03%. Regarding short-term risk, TMO is less volatile compared to MEUSW. This indicates lower risk in terms of short-term price fluctuations for TMO.Check MEUSW's competition here
PAREXEL Intl Corp. (NASDAQ: PRXL)
TMO vs PRXL Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, PRXL has a market cap of 0. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas PRXL's P/E ratio is 42.97. In terms of profitability, TMO's ROE is +0.13%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, TMO is more volatile compared to PRXL. This indicates higher risk in terms of short-term price fluctuations for TMO.Check PRXL's competition here
Danaher Corporation (NYSE: DHR-PA)
TMO vs DHR-PA Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, TMO's ROE is +0.13%, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, TMO is more volatile compared to DHR-PA. This indicates higher risk in terms of short-term price fluctuations for TMO.Check DHR-PA's competition here
Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX)
TMO vs OCDX Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, OCDX has a market cap of 0. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas OCDX's P/E ratio is -42.28. In terms of profitability, TMO's ROE is +0.13%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, TMO is more volatile compared to OCDX. This indicates higher risk in terms of short-term price fluctuations for TMO.Check OCDX's competition here
ENDRA Life Sciences Inc. Warrants (NASDAQ: NDRAW)
TMO vs NDRAW Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas NDRAW's P/E ratio is N/A. In terms of profitability, TMO's ROE is +0.13%, compared to NDRAW's ROE of -5.13%. Regarding short-term risk, TMO is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for TMO.Check NDRAW's competition here
BioNano Genomics, Inc. WT EXP 082123 (NASDAQ: BNGOW)
TMO vs BNGOW Comparison August 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 213.4B. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, TMO is priced at $574.30 on the NYSE, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 24.79, whereas BNGOW's P/E ratio is N/A. In terms of profitability, TMO's ROE is +0.13%, compared to BNGOW's ROE of -0.71%. Regarding short-term risk, TMO is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for TMO.Check BNGOW's competition here